Evidence map›Paper›PMID 35848648›Full record

ArticleAnnals of African medicine

Prostate cancer characteristics: A descriptive analysis of clinical features at presentation in the last decade in a black African community.

Fredrick O Ugwumba, Ikenna I Nnabugwu

Open access · greenAbstract read
In one paragraph

Article in Annals of African medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Prostate cancer in Nigeria: a scoping review and meta-analysis of current evidence on process indicators and interventions.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2025
    Pooled it
  2. High-Resolution Melting PCR-Based SNP Germline Genotyping ofDiagnostics (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Prostate Cancer Management in Nigeria: A mini-review of up-to-date treatment options.Nigerian medical journal : journal of the Nigeria Medical Association
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Fredrick O UgwumbaFaculty of Medical Sciences, College of Medicine, University of Nigeria Enugu Campus, Enugu, Nigeria.
Ikenna I NnabugwuDepartment of Surgery, Urology Unit, University of Nigeria Teaching Hospital, Enugu, Nigeria.
University of Nigeria · NGUniversity of Nigeria Teaching Hospital · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prostate cancer, previously reported as relatively rare in Nigeria, is currently the leading cancer and leading cause of cancer-related death in men. Late presentation appears to persist despite higher incidence rates and instituted awareness programs. This study assesses current prostate cancer indices at presentation to a 3 Materials and Methods: Retrospectively, the medical records of men presenting with histologically confirmed prostate cancer from January 2009 to April 2018 were reviewed. Age, spectrum and duration of clinical features, serum total prostate-specific antigen (tPSA), and prostate biopsy specimen Gleason Score (GS) at presentation were retrieved for the analysis using the SPSS software version 21. Obtained mean values and proportions were compared to reports from previous decades for observable shifts. Results: The medical records of 331 men 51-90 years of age (mean: 69.8 ± 8.0 years) were retrieved. Six (1.8%) men (median tPSA = 28.0 ng/ml; range 10.0-121.4 ng/ml) had screening-detected prostate cancer. About 72.0%, 52.0%, and 30.3% of men present with symptoms after 3 months, 6 months, and 12 months, respectively, and about 55.1% had other clinical features of disease progression beyond lower urinary tract symptoms. Symptom duration, serum tPSA (median 31.4 ng/ml; range 4.0-710.0 ng/ml), and % fPSA (median 20.6%; range 57.1%-8.6%) at presentation, as well as prevalent poorly-differentiated tumor (GS ≥7 [4 + 3] 62.2%) are yet to shift from reports from previous decades. Conclusions: Prostate cancer indices at presentation in South-eastern Nigeria, a resource-poor community in sub-Saharan Africa are yet to positively shift despite efforts at prostate cancer awareness.

Indexed as

Prostate-Specific AntigenProstatic NeoplasmsAgedBlack PeopleHumansMaleMass ScreeningMiddle AgedProstateRetrospective StudiesProstate-Specific AntigenHospital presentationNigeriaprostate cancertemporal changes

Identifiers

PMID35848648
PMCPMC9383014
OpenAlexW4285109836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.